Burnell M. Henry

FDA investigator

Appears on 22 documents from 2012 to 2026, most often at sites in North Carolina. Most often cites production record review (21 CFR 211.192).

22
Documents on file
4.3
Observations per 483
2012
First seen
2026
Most recent

What they cite most

From 91 observations

Activity by year

2012: 1, 2013: 1, 2015: 1, 2017: 2, 2018: 2, 2019: 2, 2020: 1, 2021: 3, 2022: 3, 2023: 1, 2024: 3, 2025: 1, 2026: 1

Where

North Carolina 6 · Florida 3 · Georgia 2 · New York 2 · California 1 · Germany 1

Is Burnell M. Henry coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

22 documents, newest first
FirmOpen
483 CSL Behring GmbH Emil-Von-Behring-Str. 76Feb 18, 2026 · Marburg, Germany
483 ROVI PHARMA INDUSTRIAL SERVICES S.A.Jan 31, 2025 · San Sebastián de los Reyes, Spain
483 FDA Form 483 ADMA Biologics Inc., Boca Raton, FL Dec 2024Dec 11, 2024 · Boca Raton, Florida
483 Wyeth Pharmaceutical Division of Wyeth Holdings LLCOct 17, 2024 · Sanford, North Carolina
483 Kedrion Biopharma Inc.Mar 27, 2024 · Melville, New York
483 Takeda Pharmaceutical Company LimitedNov 6, 2023 · Hikari, Japan
483 Wyeth Pharmaceutical Division of Wyeth Holdings LLCNov 18, 2022 · Sanford, North Carolina

About this profile

What does Burnell M. Henry inspect?

Burnell M. Henry appears on 22 documents on file covering 15 sites, most often in North Carolina.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Burnell M. Henry is dated Feb 18, 2026.

FDA Investigator Burnell M. Henry: 483s & Inspections · FDA Intel